Data sourced from ClinicalTrials.gov (NIH registry) Updated weekly IRB-supervised studies only
Home/PA/Lancaster
Updated August 2026 from ClinicalTrials.gov

Paid Clinical Trials in Lancaster, PA

Studies commonly pay $75 to $4,500 per completed study

431 clinical trials are currently recruiting participants within 30 miles of Lancaster. Listings below come straight from the official NIH registry, alongside the area's top-rated research centers with real Google reviews.

431studies recruiting
1+research centers nearby
6condition categories
Live from the NIH registry

Studies recruiting near Lancaster right now

Top 25 of 431 recruiting studies, sorted by proximity — each links to its official registry page

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer Phase 2, Phase 3 Interventional 10,000 participants sought
Ephrata Cancer Center — Ephrata, Pennsylvania (11.5 mi) · Sponsor: SWOG Cancer Research Network
See eligibility & contact on ClinicalTrials.gov (NCT03851445)

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia Phase 1 Interventional 40 participants sought
Penn State College of Medicine — Hershey, Pennsylvania (25.0 mi) · Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois
See eligibility & contact on ClinicalTrials.gov (NCT05500807)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia Phase 2 Interventional 222 participants sought
Penn State Children's Hospital — Hershey, Pennsylvania (25.0 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT06124157)

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Lymphoma, Large B-Cell, Diffuse Phase 2 Interventional 594 participants sought
Cancer Care Associates Of York ( Site 0174) — York, Pennsylvania (23.2 mi) · Sponsor: Merck Sharp & Dohme LLC
See eligibility & contact on ClinicalTrials.gov (NCT06890884)

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Endometrial Cancer Phase 3 Interventional 600 participants sought
Research Site — Hershey, Pennsylvania (25.0 mi) · Sponsor: AstraZeneca
See eligibility & contact on ClinicalTrials.gov (NCT06989112)

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Relapsed/Refractory Primary Central Nervous System Lymphoma Phase 3 Interventional 132 participants sought
Penn State Health Milton S Hershey Medical Center — Hershey, Pennsylvania (25.0 mi) · Sponsor: Ono Pharmaceutical Co., Ltd.
See eligibility & contact on ClinicalTrials.gov (NCT07104032)

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Carcinoma, Transitional Cell, Urinary Bladder Neoplasms Phase 3 Interventional 450 participants sought
Lancaster General Hospital - Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania (0.4 mi) · Sponsor: Eli Lilly and Company
See eligibility & contact on ClinicalTrials.gov (NCT07218380)

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Smoldering Plasma Cell Myeloma Phase 3 Interventional 288 participants sought
Penn State Milton S Hershey Medical Center — Hershey, Pennsylvania (25.0 mi) · Sponsor: ECOG-ACRIN Cancer Research Group
See eligibility & contact on ClinicalTrials.gov (NCT03937635)

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 3 Interventional 1,145 participants sought
Research Site — York, Pennsylvania (23.2 mi) · Sponsor: AstraZeneca
See eligibility & contact on ClinicalTrials.gov (NCT06129864)

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms Phase 3 Interventional 641 participants sought
Keystone Urology Specialists — Lancaster, Pennsylvania (0.4 mi) · Sponsor: Janssen Research & Development, LLC
See eligibility & contact on ClinicalTrials.gov (NCT06319820)

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer Phase 3 Interventional 1,000 participants sought
The Centers for Advanced Urology d/b/a Keystone Urology Specialist — Lancaster, Pennsylvania (0.4 mi) · Sponsor: Pfizer
See eligibility & contact on ClinicalTrials.gov (NCT07028853)

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

Transitional Cell Cancer of Renal Pelvis and Ureter Phase 3 Interventional 100 participants sought
The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center — Hershey, Pennsylvania (25.0 mi) · Sponsor: Steba Biotech S.A.
See eligibility & contact on ClinicalTrials.gov (NCT04620239)

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Phase 3 Interventional 1,200 participants sought
Cancer Care Associates Of York ( Site 0005) — York, Pennsylvania (23.2 mi) · Sponsor: Merck Sharp & Dohme LLC
See eligibility & contact on ClinicalTrials.gov (NCT06136559)

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Extensive Stage-small Cell Lung Cancer Phase 1, Phase 2 Interventional 123 participants sought
Lancaster General Hospital - Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania (0.4 mi) · Sponsor: Daiichi Sankyo
See eligibility & contact on ClinicalTrials.gov (NCT06362252)

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer Phase 3 Interventional 600 participants sought
Reading Hospital - McGlinn Cancer Institute — West Reading, Pennsylvania (27.5 mi) · Sponsor: Hoffmann-La Roche
See eligibility & contact on ClinicalTrials.gov (NCT06793215)

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Percutaneous Coronary Intervention, Peripheral Endovascular Intervention Phase 4 Interventional 6,000 participants sought
Penn Lancaster General Health Research Institute — Lancaster, Pennsylvania (0.4 mi) · Sponsor: Duke University
See eligibility & contact on ClinicalTrials.gov (NCT06909565)

A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)

Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure Phase 2 Interventional 48 participants sought
Penn State Hershey ALS Clinic — Hershey, Pennsylvania (25.0 mi) · Sponsor: University of Pennsylvania
See eligibility & contact on ClinicalTrials.gov (NCT07071935)

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma Phase 2 Interventional 189 participants sought
UPMC Memorial — York, Pennsylvania (23.2 mi) · Sponsor: ECOG-ACRIN Cancer Research Group
See eligibility & contact on ClinicalTrials.gov (NCT02734537)

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

Peripheral Nerve Injuries Phase 2 Interventional 40 participants sought
Wellspan Health — York, Pennsylvania (23.2 mi) · Sponsor: Major Extremity Trauma Research Consortium
See eligibility & contact on ClinicalTrials.gov (NCT04789044)

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Triple-Negative Breast Cancer Phase 3 Interventional 1,530 participants sought
Cancer Care Associates Of York ( Site 9517) — York, Pennsylvania (23.2 mi) · Sponsor: Merck Sharp & Dohme LLC
See eligibility & contact on ClinicalTrials.gov (NCT06393374)
Actively enrolling

Studies you may be able to join near Lancaster

These studies are recruiting through partner research networks. We may be paid a referral fee if you complete their screening form — this never changes what you pay (nothing) or the compensation the study offers you.

Research study for alcohol-related liver damage

Enrolling US adults aged 18 to 70 with alcohol-induced liver damage and a history of heavy drinking. Not open to people with a recent stroke, heart attack, dialysis, or who take blood thinners.

Screening is free and takes a few minutes. Eligibility and any compensation are confirmed by the study team, not by this site.

Check your eligibility

Research study for bladder problems after spinal cord injury

This study is enrolling US adults aged 18 to 75 living with chronic involuntary bladder leakage caused by a spinal cord injury, for research including investigational gene therapy approaches. The study team confirms eligibility and any compensation before enrollment.

Screening is free and takes a few minutes. Eligibility and any compensation are confirmed by the study team, not by this site.

Check your eligibility
Google-rated

Top-rated research centers in Lancaster

Dedicated clinical research sites near you — with their real Google ratings, reviews and contact details

Clinical Research Center-Reading

2760 Century Blvd #3, Reading, PA 19610
(610) 375-2466

Clinical trials in Lancaster: what's recruiting

The Lancaster area currently has 431 studies open to new participants, according to the ClinicalTrials.gov registry maintained by the U.S. National Institutes of Health. Among the studies closest to Lancaster, the most active research areas are:

  • Cancer & Oncology16 studies
  • Liver & Kidney3 studies
  • Diabetes & Metabolism1 studies
  • Immune & Skin1 studies
  • Heart & Vascular1 studies

Every listing shows the study phase, the recruiting site and its distance from Lancaster, and links to the official registry page where eligibility criteria and study contacts are published. Compensation is set by each sponsor: industry surveys report typical payments of $75 to $4,500 per completed study, with short observational studies at the low end and multi-visit or overnight Phase 1 studies at the high end.

How to enroll in a paid study in Lancaster

Start with a study whose condition matches your profile — or a healthy-volunteer study if you have no diagnosis. Contact the research site through the registry page, complete a short phone screen, then attend an in-person screening visit. If you qualify, the study team walks you through the informed consent document, which details every procedure, risk and payment before you commit. You can withdraw at any point, and enrollment is always free.

Lancaster participants can also register with the dedicated research centers listed above — many maintain volunteer databases and call when a matching study opens — or sign up for our email alert below to hear when a new study starts recruiting within 30 miles of your ZIP code.

Frequently asked questions

How much do paid clinical trials in Lancaster pay?
Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.
Are clinical trials in Lancaster safe?
Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.
How do I join a study in Lancaster, PA?
Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.
Is compensation for clinical trials taxable?
In the U.S., clinical trial compensation is generally considered taxable income, and research sites may issue a 1099 form for payments above $600 in a year. Reimbursements for travel or meals are typically treated differently. Consult a tax professional for your situation.
Can I be in more than one clinical trial at a time?
Generally no — most studies exclude participants currently enrolled in another trial, and paid Phase 1 studies enforce a washout period (often 30 days or more) between studies. Frequent healthy volunteers in Lancaster typically complete one or two studies per year.

Paid clinical trials near Lancaster

Other metros within reach

York, PA447 Reading, PA280 Harrisburg, PA402 Baltimore, MD1,650 Allentown, PA234 Philadelphia, PA2,177 Frederick, MD262 Washington, DC2,362

By condition

Eligibility and exclusions, condition by condition

Alcoholic Liver Disease in Lancaster Bladder Issues Due To Spinal Cord Injury in Lancaster All conditions

More of PA

Philadelphia2,177 Pittsburgh1,232 York447 Harrisburg402 Reading280 Allentown234 Scranton99 Erie89

New paid studies open every week

Get an email when a new clinical trial starts recruiting within 30 miles of your ZIP code. No spam — only real studies from the NIH registry.

By subscribing you agree to receive study alert emails. Unsubscribe anytime in one click.

Get free trial alerts